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Thromboembolism is central to atrial fibrillation (AF) related morbidity. 1 The pathogenesis of intra-cardiac thrombus formation in AF is linked to each component of Virchow's triad including atrial stasis, endothelial dysfunction, and a systemic hypercoagulable state. 2 Although embolism of cardiac thrombi can involve any vascular territory, there has been a historical focus on cerebral embolism, an outcome associated with substantial disability and mortality. 3 In contrast to the well-characterized risk and sequelae of cerebral embolism, much less is known regarding the clinical risk factors and outcomes associated with systemic embolic events (SEEs) in AF. 1, [4] [5] [6] In this issue of Circulation, Bekwelem and colleagues improve our understanding of the epidemiology and prognostic implications of systemic embolism in AF. 7 They retrospectively pooled data from four published randomized trials of anti-platelet or anticoagulant therapy in AF patients encompassing a total of 37,973 individuals ( Table 1) . [8] [9] [10] [11] The investigators readjudicated suspected SEEs using a harmonized classification scheme. An SEE was defined by both clinical and objective evidence of sudden loss of end-organ perfusion. They then examined the risks of both 30-day and long-term morbidity in relation to SEEs.
Overall, 221 SEEs occurred in 219 individuals during a mean follow-up of 2.4 years. The incidence of SEEs (0.24/100 person-years) was lower than cerebral embolism (1.92/100 personyears) and comprised 12% of clinically-recognized thromboembolic events. Anatomically, about 60% of SEEs involved the lower extremities, whereas about 30% occurred in the visceralmesenteric system, and only 11% occurred in the upper extremities. Most patients underwent an invasive procedure as part of their clinical management. SEEs were associated with similar and significant 30-day mortality when compared to stroke alone (24% vs. 25%). SEEs were associated with about a 4-fold increased risk of long-term mortality, as compared to a nearly 7fold increased risk of mortality associated with ischemic stroke. pooled data from four published randomized trials of anti-platelet or anticoagulant nt nt t t the he hera ra rapy py py i i in n n A AF A patients encompassing a total of 37,973 individuals ( Table 1) . [8] [9] [10] [11] The investigators re- The incidence and anatomic location associated with cardioembolism may also be related to other factors. Anatomic distribution is generally influenced by the character of arterial branching and the course of blood flow. 1, 6 Increased thrombus size has been reported to favor peripheral rather than cerebral embolic destination. 12 Limited histochemical comparison of central versus peripheral thrombi in AF is suggestive of differing biology with in situ thrombi comprised primarily of amorphous debris and fibrin in contrast to embolic thrombi comprised of fibrin and platelets. 13 Regardless of whether patients are predisposed to specific embolic destinations, the contribution by Bekwelem and colleagues underscores the substantial morbidity associated with embolism of any kind.
Systemic Embolism in AF -Unique Events or Additional Embolic Destinations?

Clinical and Therapeutic Implications of Identifying SEE Risk in AF
Given that several SEE risk factors (eg. female gender, peripheral vascular disease, prior myocardial infarction) are included in stroke prediction algorithms it is unlikely that the report by Bekwelem et al. 7 will significantly modify the decision to initiate anticoagulation. Indeed, the compared to stroke in AF. 12 The incidence and anatomic location associated with cardioembolism may also be related (Figure 1) ? 15, 16 Such initiatives may be costeffective for stroke prevention 17 and are currently being evaluated. [18] [19] [20] Similarly, would enhanced cardiac rhythm monitoring to detect AF alter management in patients with visceral embolism or peripheral ischemia without known AF, akin to efforts to identify a cause for cryptogenic stroke? 21 At what expense would AF prevention prove cost-effective altogether for the reduction of embolic morbidity, if it were achievable? Practically, answering such questions may be challenging owing to the relatively low event rates and large sample sizes necessary.
Therefore, at present it appears prudent to exercise increased vigilance for AF detection in patients either at high-risk for systemic embolic events or with unexplained peripheral ischemia that may be of embolic origin.
Bekwelem and colleagues have contributed significantly to our understanding of the spectrum of thromboembolic risk in patients with AF. Their report provides us with estimates of the incidence of SEEs, the arterial beds most commonly affected, and the morbidity associated with such events. By opening our eyes, these data help us "SEE" embolic risk more clearly.
Ultimately such clarity will guide more effective application of therapies to stem the rising tide of AF 22 and thromboembolic morbidity. the role of enhanced surveillance may be considered for patients at increased risk of AF, stroke, and systemic embolic events (SEEs). The CHARGE-AF score (inclusive of age, race, height, weight, blood pressure, smoking status, use of anti-hypertensive medication, diabetes, history of myocardial infarction and heart failure) has demonstrated discrimination in the prediction of AF. 15 Post-diagnosis, risk assessment and implementation of thromboembolism prophylaxis is often guided by the CHA 2 DS 2 -VASc algorithm. 16 The circles display the relatively increased 
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